Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ATRX loss |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ATRX loss | glioblastoma | sensitive | Doxorubicin | Preclinical | Actionable | In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505). | 26936505 | |
ATRX loss | glioblastoma | sensitive | Irinotecan | Preclinical | Actionable | In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505). | 26936505 | |
ATRX loss | glioblastoma | sensitive | Topotecan | Preclinical | Actionable | In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505). | 26936505 | |
ATRX loss | high grade glioma | predicted - sensitive | Talazoparib | Preclinical - Cell culture | Actionable | In a preclinical study, Talzenna (talazoparib) treatment inhibited viability of immortalized astrocytes with loss of ATRX in culture (PMID: 34118569). | 34118569 | |
ATRX loss | high grade glioma | predicted - sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment inhibited viability of immortalized astrocytes with loss of ATRX in culture (PMID: 34118569). | 34118569 | |
ATRX loss | high grade glioma | predicted - sensitive | Ceralasertib + Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the combination of Ceralasertib (AZD6738) and Lynparza (olaparib) synergized to inhibit viability of immortalized astrocytes with loss of ATRX in culture (PMID: 34118569). | 34118569 |